Modulation of renal epithelial barrier function by mitogen-activated protein kinases (MAPKs): mechanism of cyclosporine A-induced increase in transepithelial resistance

BACKGROUND: Cyclosporine A (CsA) has been shown to increase transepithelial resistance in Madin-Darby canine kidney (MDCK) cells, and the mechanism may involve altered phosphorylation of junctional proteins. In this study, we examine the effect of the extracellular signal-regulated protein kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) pathways on the basal transepithelial resistance (TER) and on the CsA-induced increase in TER across MDCK monolayers. Here we present evidence that CsA may be mediating some of its effects through activation of the ERK 1/2 MAPK pathway. METHODS: MDCK cells were treated with CsA (4.2 micromol/L) and paracellular permeability was assessed by measuring TER. The role of the ERK 1/2 and the p38 MAPK pathways in modulating TER was investigated using the inhibitors PD98059 and U0126 for ERK 1/2 and SB203580 for p38. ERK 1/2 and p38 phosphorylation/activation was also examined by Western blot analysis. RESULTS: CsA (4.2 micromol/L) increased the TER of MDCK monolayers. The ERK 1/2 inhibitor PD98059 decreased basal TER and also ameliorated the CsA-induced increase in TER. Similar results were found with the U0126 inhibitor of ERK 1/2. The p38 inhibitor SB203580 had no effect on the basal TER of the monolayers, however, SB203580 significantly augmented the CsA-induced increase in TER. CsA was shown to significantly activate ERK 1/2 and this activation by CsA was prevented by PD98059. Inhibition of the p38 pathway by SB203580 also resulted in activation of ERK 1/2 and this activation of ERK 1/2 was further enhanced by CsA. No effect of CsA or the inhibitors PD98059 or SB203580 on p38 phosphorylation was detected. CONCLUSION: The results presented here suggest that activation of the ERK 1/2 MAPK cascade is important in the regulation of the paracellular permeability in MDCK cells. Activation of this pathway appears to be pivotal to the CsA-induced increase in TER.     

Differential Activation of Mitogen-activated Protein Kinases in Ischemic and Anesthetic Preconditioning

Background: Accumulating evidence pinpoints to the pivotal role of mitogen-activated protein kinases (MAPKs) in the signal transduction underlying cardiac preconditioning.

Methods: PD98059, an inhibitor of extracellular signal-regulated protein kinase (MEK-ERK1/2), and SB203580, an inhibitor of p38 MAPK, were used to evaluate the role of MAPKs with respect to postischemic functional recovery in isolated perfused rat hearts subjected to ischemic preconditioning (IPC) and anesthetic preconditioning (APC). Western blot analyses were used to determine the degree of ERK1/2 and p38 MAPK activation after the application of the preconditioning stimulus and after ischemia-reperfusion. Immunohistochemical staining served to visualize subcellular localization of activated MAPKs.

Results: PD98059 and SB203580 abolished postischemic functional recovery in IPC but not in APC. IPC but not APC markedly activated ERK1/2 and p38 MAPK, which were abrogated by coadministration of the specific blockers. Conversely, IPC and APC enhanced ERK1/2 activity after ischemia-reperfusion as compared to nonpreconditioned hearts, and IPC in addition enhanced p38 MAPK activity. Coadministration of PD98059 and SB203580 during IPC but not during APC inhibited postischemically enhanced MAPK activities. Moreover, chelerythrine and 5-hydroxydecanoate, effective blockers of IPC and APC, annihilated IPC- and APC-induced enhanced postischemic responses of MAPKs. Finally, administration of PD98059 during ischemia-reperfusion diminished the protective effects of IPC and APC. Immunohistochemistry revealed increased ERK1/2 activity primarily in intercalated discs and nuclei and increased p38 MAPK activity in the sarcolemma and nuclei of IPC-treated hearts.     

Transforming growth factor-beta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation.

BACKGROUND: Transforming growth factor-beta (TGFbeta)-induced epithelial-myofibroblast transdifferentiation is a central mechanism contributing to the pathogenesis of progressive tubulo-interstitial fibrosis. We wanted to dissect the role of extracellular signal-regulated protein kinase (ERK1,2), p38 mitogen-activated protein kinase (p38 MAPK) and the receptor-regulated Smad proteins in the regulation of alpha-smooth muscle cell actin (alphaSMA) expression, a hallmark of myofibroblast formation, induced by TGFbeta in renal proximal tubular cells. METHODS: Activation of signalling molecules was assessed by western blotting using phospho-specific antibodies. To specifically interfere with signalling cascades, porcine proximal tubular cells (LLC-PK/AT1) were infected with recombinant replication-deficient adenoviruses. In other experiments, specific kinase inhibitors were used. The alphaSMA synthesis was assessed by western blotting or immunofluorescent staining of cellular alphaSMA. To assess the regulation of the alphaSMA promoter, tubular cells were transiently transfected with a 785 bp alphaSMA promoter-luciferase reporter construct and vectors interfering with the Smad pathway. RESULTS: Blocking ERK1,2 activation with PD98059 or p38 MAPK with SB 203580 potently inhibited the TGFbeta-induced alphaSMA synthesis in renal tubular cells. Adenoviral expression of dominant negative (DN) p38beta but not of p38alpha potently inhibited alphaSMA expression. Furthermore, adenoviral expression of DN MKK6b but not of DN MKK3b caused a substantial inhibition of the TGFbeta effect, confirming the role of p38beta in the regulation of TGFbeta-induced alphaSMA expression. Finally, inhibiting the Smad pathway with adenovirally delivered Smad7 and DN Smad3 also blocked TGFbeta-induced alphaSMA synthesis. CONCLUSION: TGFbeta-induced alphaSMA expression is regulated by the coordinated activation of a complex system of parallel MAPK and Smad signalling pathways in renal proximal tubular cells during epithelial-mesenchymal transdifferentiation.     

缺氧时丝裂原激活蛋白激酶类对人肾小管上皮细胞富含半胱氨酸蛋白61基因转录活性的调控

目的 探讨丝裂原激活蛋白激酶类（MAPKs）对缺氧条件下人近端肾小管上皮细胞（HKC）中富含半胱氨酸蛋白61（Cyr61）基因转录活性的调控机制。方法 缺氧培养HKC，Northern印迹检测Cyr61mRNA表达；Western印迹检测Cyr61、p38、细胞外信号调节激酶（ERK1／2）、c—Jun—N末端蛋白激酶（JNK）以及缺氧诱导因子1c（HIF-1α）的表达。构建含有人Cyr61基因启动子的报告基因Cyr61-luc质粒，将其单独或者分别与表达活性MAPKs的质粒Ca—MEK1和Ca—MKK6共同瞬时转染HKC。通过荧光素酶活性检测观察缺氧、MAPKs抑制剂和MAPKs活性酶对Cyr61基因转录活性的调控。结果 缺氧时HKC表达cyr61、HIF-1α增高，ERK1／2、JNK、p38总量不变，而其各自的磷酸化形式均明显增加。HKC转染Cyr—luc后，p38通路抑制剂SB203580和ERK通路抑制剂PD98059显著抑制缺氧时Cyr61的转录活性，两者协同作用时抑制作用显著增强。Ca—MEK1与Cyr—luc共转染HKC后，Cyr61转录活性无改变；而Ca—MKK6与Cyr—luc共转染后，Cyr61转录活性显著增高。对缺氧培养的HKC，PD98059处理使HIF-1α和Cyr61蛋白表达显著降低；SB203580处理可显著降低Cyr61蛋白表达，但对HIF-1α无影响。结论 在HKC中，缺氧可通过p38通路直接上调Cyr61基因启动子活性，也可通过ERK1／2途径促进HIF-1α表达，间接调节Cyr61基因启动子活性。     

Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning

BACKGROUND: Accumulating evidence pinpoints to the pivotal role of mitogen-activated protein kinases (MAPKs) in the signal transduction underlying cardiac preconditioning. METHODS: PD98059, an inhibitor of extracellular signal-regulated protein kinase (MEK-ERK1/2), and SB203580, an inhibitor of p38 MAPK, were used to evaluate the role of MAPKs with respect to postischemic functional recovery in isolated perfused rat hearts subjected to ischemic preconditioning (IPC) and anesthetic preconditioning (APC). Western blot analyses were used to determine the degree of ERK1/2 and p38 MAPK activation after the application of the preconditioning stimulus and after ischemia-reperfusion. Immunohistochemical staining served to visualize subcellular localization of activated MAPKs. RESULTS: PD98059 and SB203580 abolished postischemic functional recovery in IPC but not in APC. IPC but not APC markedly activated ERK1/2 and p38 MAPK, which were abrogated by coadministration of the specific blockers. Conversely, IPC and APC enhanced ERK1/2 activity after ischemia-reperfusion as compared to nonpreconditioned hearts, and IPC in addition enhanced p38 MAPK activity. Coadministration of PD98059 and SB203580 during IPC but not during APC inhibited postischemically enhanced MAPK activities. Moreover, chelerythrine and 5-hydroxydecanoate, effective blockers of IPC and APC, annihilated IPC- and APC-induced enhanced postischemic responses of MAPKs. Finally, administration of PD98059 during ischemia-reperfusion diminished the protective effects of IPC and APC. Immunohistochemistry revealed increased ERK1/2 activity primarily in intercalated discs and nuclei and increased p38 MAPK activity in the sarcolemma and nuclei of IPC-treated hearts. CONCLUSIONS: Although MAPKs may orchestrate cardioprotection as triggers and mediators in IPC, they are devoid of triggering, but they may have mediator effects in APC.     

p38MAPK与 ERK1/2的协同效应及对成骨细胞分化的调控

 目的探讨骨髓间质干细胞(bone marrow mesenchymal stem cells,BMSCs)向成骨细胞分化过程中 p38MAPK与 ERK1/2的协同效应及其机制。方法以成骨细胞分化添加剂诱导小鼠 BMSCs向成骨细胞分化,测定碱性磷酸酶活性和钙沉积量。检测磷酸化 p38MAPK和磷酸化 ERK1/2(p-ERK1/2)的表达水平评估通路的激活状况。以 SB203580或 PD98059阻断 p38MAPK或 ERK1/2通路,观察对成骨细胞分化的影响。以 SB203580或亚砷酸钠阻断或激活 p38MAPK通路,观察 p-ERK1/2的变化。以冈田酸抑制蛋白磷酸酯酶 2A(protein phosphatases type 2A,PP2A)活性,观察 p-ERK1/2的变化及对成骨细胞分化的影响。通过免疫共沉淀实验观察 PP2A和 ERK1/2间的结合及 SB203580对结合的影响。结果成骨细胞分化添加剂诱导 BMSCs向成骨细胞分化的过程伴有 ERK1/2和 p38MAPK通路的激活, SB203580剂量±赖性抑制成骨细胞分化,PD98059剂量±赖性增强成骨细胞分化。 SB203580使 p-ERK1/2表达增加,亚砷酸钠减弱其表达。冈田酸使 p-ERK1/2表达增加,并使成骨细胞分化受到抑制。 PP2A可直接与 ERK1/2结合,SB203580使 PP2A与 ERK1/2的结合减弱。结论 p38MAPK可通过 PP2A与 ERK1/2产生协同效应,并调节 BMSCs向成骨细胞分化。     

ERK and p38 MAP kinase are required for rat renal development

BACKGROUND: We previously demonstrated that extracellular signal-regulated protein kinase (ERK) and p38 mitogen-activated protein (MAP) kinase (p38) are strongly expressed in the embryonic kidney. In the present study, we investigated the role of ERK and p38 during kidney development. METHODS: Rat metanephroi were cultured from 15-day-old embryos, and exposed to inhibitors of MEK, an activator of ERK, PD98059 (300 micromol/L), U0126 (10 micromol/L), or a p38 inhibitor SB203580 (30 micromol/L) 24 to 120 hours after the start of culture. Growth of metanephroi was measured by surface area and thymidine incorporation. Ureteric buds and glomeruli were identified by labeling with Dolichos biflorus lectin and peanut agglutinin, respectively. PCNA staining and TUNEL assay were performed on kidney sections. The level of apoptosis was evaluated by examining DNA ladder formation. RESULTS: Growth of metanephroi was significantly inhibited by SB203580 but not by PD98059 or U0126. Ureteric bud branching was not affected by SB203580 or MEK inhibitors. Glomerular number was markedly reduced by SB203580 and to a lesser extent by U0126 (14 +/- 2 and 48 +/- 10% of controls, respectively). On histological examination, the number of tubuloglomerular structures was reduced in MEK inhibitor-treated metanephroi compared to controls. Very few mesenchymal condensates were observed in kidneys incubated with SB203580. PCNA-positive cells were reduced in SB203580-treated metanephroi compared to control and PD98059-treated kidneys. Apoptosis was increased in SB203580-treated kidneys and to a lesser extent in PD98059-treated cultures. CONCLUSIONS: Both ERK and p38 are required for renal development. ERK appears to play a role in nephrogenesis and p38 for kidney growth and nephrogenesis.     

两种不同病理类型肾病患者尿蛋白诱导肾小管上皮细胞上调表达趋化因子及其分子信号机制研究

目的 观察不同病理类型肾病患者尿蛋白对人近端肾小管上皮细胞（HK-2）分泌趋化因子的影响并探讨其分子信号机制。 方法 所有患者均经临床和肾穿刺活检确诊为原发性局灶节段性肾小球硬化（FSGS）或微小病变性肾病（MCD）。以超滤法浓缩提取患者尿中总蛋白，分别刺激体外培养的HK-2细胞。RT-PCR检测调节正常T细胞表达和分泌的细胞因子（RANTES）及巨噬细胞移动抑制因子（MIF）的mRNA水平。免疫荧光、ELISA及流式细胞仪检测蛋白水平的表达。Western 印迹法检测p38 MAPK和胞外信号调节激酶（ERK）水平。特异性抑制剂SB203580抑制p38磷酸化；PD98059则用于抑制ERK磷酸化。 结果 两种尿蛋白成分有差异，FSGS患者尿蛋白中含有更多的大分子量蛋白。两种尿蛋白均刺激HK-2细胞RANTES及MIF表达上调，而FSGS患者尿蛋白刺激作用更强。两种尿蛋白均显著激活HK-2细胞内ERK和p38 MAPK信号通路。特异性抑制剂分别抑制ERK或p38 MAPK的活化后，FSGS患者尿蛋白介导的RANTES和MIF的上调表达作用可被SB203580或PD98059抑制，而MCD患者尿蛋白的刺激作用却仅能被SB203580所阻断。 结论 FSGS肾病患者的尿蛋白比MCD患者的尿蛋白有更强的上调HK-2细胞RANTES及MIF表达的作用。两种尿蛋白介导趋化因子上调表达的分子信号机制存在差异。     

丝裂原活化蛋白激酶类和蛋白激酶C在转化生长因子β1诱导肾小管细胞结缔组织生长因子表达中的作用

目的了解转化生长因子β1（TGF-β1）诱导肾小管细胞结缔组织生长因子（CTGF）表达的机制，特别是蛋白激酶C（PKC）和丝裂原活化蛋白激酶（MAPK）在CTGF基因表达中的作用及其对Smad磷酸化的影响。方法分别应用PKC抑制剂G06850以及MAPK的3个组成成分ERK、JNK和p38MAPK的抑制剂PD98059、U0126、SP600125和SB203580阻断相应通路，观察其对TGF．131诱导的CTGF表达以及Smad2／Smad3磷酸化的影响。结果TGF-β1（5μg／L）以时间依赖方式诱导HK-2细胞中Smad2／Smad3的磷酸化，从基础值0．87±0．09上升至2h时高峰2．350±0.11。PKC抑制剂G06850（5μmol／L）和ERK抑制剂PD98059（10μmol／L）、U0126（10μmol／L）可部分抑制TGF-β1诱导的CTGF表达，而p38MAPK抑制剂SB203580（20μmol／L）和JNK抑制剂SP600125（10μmol／L）对TGF-β1诱导的CTGF的表达无影响。PKC抑制剂G06850（5μmol／L）可减少TGF-β1诱导的Smad2／Smad3磷酸化，而ERK抑制剂PD98059（10μmol／L）和U0126（10μmol／L）对Smad2／Smad3的磷酸化没有影响。结论在肾小管上皮细胞中，TGF-β1诱导CTGF的表达需要PKC和Ras／MEK／ERK的参与。PKC以Smad依赖的方式参与肾小管上皮细胞中TGF-β1诱导的CTGF的表达，而Ras／MEK／ERK对CTGF表达的调节不依赖于Smads。     

p38丝裂原活化蛋白激酶信号转导通路在严重烧伤大鼠枯否细胞肿瘤坏死因子α和白细胞介素1β产生中的作用

目的 探讨p38丝裂原活化蛋白激酶(MAPK)信号转导通路在严重烧伤大鼠枯否细胞(KCs)促炎性细胞因子肿瘤坏死因子α(TNF-α)和白细胞介素1β(IL-1β)产生中的作用。方法 健康成年的雄性SD大鼠32只,随机分为：假烫组;假烫 SB203580组;烧伤对照组;烧伤 SB203580组,每组8只。假烫或烧伤24h后分离出肝脏KCs,培养18h后加入50ng／ml的LPS进行刺激,18h后取上清液,用酶联免疫吸附法(ELISA)测定TNF-α和IL-1β的含量,并收集KCs,实时逆转录聚合酶链反应检测KCs内TNF-α和IL-1β mRNA表达的改变,蛋白印迹(Western blot)法检测KCs中p38MAPK和JNK活性的变化。结果 烧伤大鼠分离出的KCs培养上清液中TNF-α和IL-1β含量、KCs中TNF-α和IL-1β mRNA的表达均较假烫组的明显增强,同时KCs中p38 MAPK活性和JNK活性升高,SB203580能显著抑制大鼠KCs上清液中TNF-α和IL-1β含量、KCs中TNF-α和IL-1β mRNA的表达和p38MAPK活性的升高,对JNK活性无影响。结论p38MAPK信号转导通路介导了严重烧伤大鼠KCs促炎性细胞因子TNF-α和IL-1β的产生。     

Cardiopulmonary bypass reduces peripheral microvascular contractile function by inhibition of mitogen-activated protein kinase activity

BACKGROUND: Mitogen-activated protein kinases (MAPK) have been implicated in pathophysiologic responses to cardiopulmonary bypass (CPB). MAPK are deactivated by phosphatases, such as MAPK phosphatase-1 (MKP-1). We hypothesized that MAPK mediate peripheral microvascular contractile dysfunction caused by CPB in humans. METHODS: Skeletal muscle was harvested before and after CPB. Protein levels of MKP-1 and activated extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 were measured. MKP-1 gene expression was measured. Peripheral microvessel responses to vasopressors were studied by videomicroscopy. Contractile function also was measured after MAPK inhibition with PD98059 (ERK1/2) and SB203580 (p38). ERK1/2, p38, and MKP-1 were localized by immunohistochemistry and in situ hybridization. RESULTS: ERK1/2 and p38 activity was decreased in peripheral tissue after CPB. MKP-1 was increased after CPB. Contractile responses of peripheral arterioles to phenylephrine and vasopressin were decreased after CPB. Microvessel reactivity also was reduced after treatment with PD98059 and SB203580. ERK1/2, p38, and MKP-1 localized to peripheral arterioles in tissue sections. CONCLUSIONS: CPB reduces ERK1/2 and p38 activity in peripheral tissue, potentially by MKP-1. Contractile responses of peripheral arterioles to phenylephrine and vasopressin are dependent on ERK1/2 and p38 and are decreased after CPB. These results suggest that alterations in MAPK pathways in part regulate peripheral microvascular dysfunction after CPB in humans.     

beta1-integrin-ligand disengagement induces in vitro capillary tube disruption mediated by p38 MAPK activity

BACKGROUND: Disrupting cell-matrix interactions may lead to capillary injury as seen in sepsis and transplant rejection. Previously, we demonstrated capillary disruption mediated by beta1-integrin-ligand disengagement. We now determine whether p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathways are involved in this capillary injury. METHODS: Endothelial capillaries on Matrigel were preincubated with a p38 MAPK inhibitor (SB203580), ERK pathway inhibitor (PD98059), or dimethyl sulfoxide. Subsequently, a beta1-integrin blocking (P5D2) or an irrelevant antibody was added. After 24 hours, capillary integrity was quantified as capillary intersections/well. Antibody-treated cell lysates then were immunoprecipitated with either a phospho-p38 MAPK or phospho-ERK1/2 antibody. Kinase activity was measured with ATF-2 and Elk-1 fusion proteins as substrates for p38 MAPK and ERK, respectively, followed by Western blotting. RESULTS: P5D2 disrupted capillary tubes. Increased p38 MAPK activity at 8 hours and ERK activity at 2 and 8 hours were seen in P5D2-treated lysates. Preincubation with SB203580, but not with PD98059 or DSMO, significantly reduced capillary tube disruption. CONCLUSIONS: The beta1-integrin-ligand disengagement resulted in capillary disruption and stimulated p38 MAPK and ERK activity. In spite of activation of both pathways, the p38 MAPK but not the ERK pathway inhibitor prevented beta1-integrin antibody effects. Inhibiting p38 MAPK may mitigate capillary injury associated with sepsis and transplant rejection.     

氧化-低密度脂蛋白诱导系膜细胞转录激活蛋白1活化的信号转导通路

目的 观察氧化—低密度脂蛋白(ox-LDL)诱导系膜细胞转录激活蛋白1(AP—1)活化的作用，探讨AP—1活化的上游信号转导机制。方法 大鼠肾小球系膜细胞随机分为正常细胞组，ox-LDL处理组和ox—LDL 蛋白激酶抑制剂组。采用western blot测定丝裂原激活的蛋白激酶(MAPK)家族磷酸化水平，采用凝胶迁移率实验观察蛋白激酶抑制剂bisindo1ylmimideiI、H89、genistein、PD98059及SB203580对ox-LDL诱导系膜细胞AP—1活性的影响。结果 ox-LDL呈浓度和时间依赖性激活JNKl／SAPK(stress activated protein kinase)、p38MAPK磷酸化(P＜0．05)，而ox-LDL对p44/／42MAPK磷酸化无影响(P＞0．05)。bisindo1ylmaleimide I浓度为50、100、200nmol/L时均显著抑制ox-LDL诱导系膜细胞AP—1活性。H89剂量为0．5、5μmol/L时，AP—1活性显著受抑制。genistein浓度为25、50μmol/L时并不抑制ox-LDL诱导AP—1活性，浓度达100μmol/L时则显著抑制ox-LDL诱导系膜细胞AP—1活性。SB203580和PD98059均不能抑制ox-LDL诱导AP—1活性。结论PKC、PKA及PTK等多种蛋白激酶参与对ox-LDL诱导系膜细胞AP—1活性的调控。     

Immune suppression in polymicrobial sepsis: differential regulation of Th1 and Th2 responses by p38 MAPK

BACKGROUND: Studies have indicated that a shift from a Th1 to a Th2 response occurs that contributes to the late immunosuppression seen during sepsis. However, the mechanism by which this occurs is unknown. In this regard, mediators released in response to sepsis are thought to upregulate a family of stress-induced mitogen-activated protein kinases (MAPKs), such as JNK, ERK, and p38 MAPK, which may play a role in this process. MATERIALS AND METHODS: To determine the role of MAPK in immune suppression, we induced polymicrobial sepsis in C3H/HeN male mice using cecal ligation and puncture (CLP). Splenic lymphocytes were harvested 24 h post-CLP and stimulated with the T-cell mitogen concanavalin A, and the expression and activation of these MAPKs were assessed by Western analysis. To determine the extent to which these MAPKs may have an impact on splenic immune function, cells were pretreated with a 10 microM concentration of the p38 MAPK inhibitor SB203580 or the MEK inhibitor PD98059 or with DMSO vehicle. The cells were then stimulated with 2.5 microg/ml of the T-cell mitogen concanavalin A, and cytokine release was then determined (by ELISA). RESULTS: In the lymphocytes from CLP mice no JNK signal was detected, however, p38 expression and activation were markedly (P < 0.05, n = 6) increased. In contrast, the expression of activated ERK markedly decreased following septic challenge. The results indicate that p38 MAPK inhibition with SB203580 suppressed the sepsis-induced augmentation of interleukin-10 release while restoring the suppressed Th1 cytokine interleukin-2 release typically encountered following sepsis. Inhibition of ERK had no effect on cytokine release. Neither PD98059 nor SB203580 had an effect on interferon gamma release or on proliferative capacity. CONCLUSION: This would indicate that the induction of p38 MAPK activation in splenocytes contributes to the immunosuppression seen in late sepsis.     

结缔组织生长因子诱导人近端肾小管上皮细胞整合素连接激酶的表达及与激酶信号途径的关系

目的探讨结缔组织生长因子（CTGF）对人近端肾小管上皮细胞系HK-2整合素连接激酶（ILK）表达的影响，以及丝裂原激活蛋白激酶（MAPK）和磷脂酰肌醇3激酶（P13-K）途径对该因子表达的影响。方法用不同浓度的CTGF作用HK-2细胞24h及50μg／L的CTGF作用HK-2细胞不同时间，以实时PCR和Western印迹方法检测ILKmRNA及蛋白的表达。用信号通路特异性抑制剂预处理，观察其对CTGF的干预作用。结果CTGF呈时间及浓度依赖性诱导人近端肾小管上皮细胞ILK蛋白表达。5、20、50μg／L的CTGF可使ILK表达量分别增加为对照组的3．284、5．103、5．638倍。50μg／LCTGF使ILK的表达在6h开始升高，高峰在48h（为对照组5．740倍），MEK抑制剂PD98059和P13．K抑制剂LY294002显著降低CTGF诱导的HK-2细胞ILK基因和蛋白的表达（P均〈0．05）。p38MAPK抑制剂SB203580对CTGF诱导的ILK表达无显著影响。结论CTGF能诱导HK-2细胞ILK蛋白的表达，该作用可能与ERK1／2和P13-K信号途径激活有关。     

丝裂原活化蛋白激酶对大鼠成骨细胞TRPV6表达的影响

目的探讨丝裂原活化蛋白激酶对大鼠成骨细胞瞬时性受体电位香草精受体6（transient receptor poten-tial vanilloid receptor 6,TRPV6）表达的影响。方法采用Wistar大鼠乳鼠,连续酶消化法提取成骨细胞并培养。根据组织形态学、改良Kaplow氏成骨细胞碱性磷酸酶染色、矿化结节茜素红染等方法进行鉴定。实验分组：a）正常对照组;b）PD组（PD98059 5μmol/L;PD98059 10μmol/L;PD98059 20μmol/L）;c）SB组（SB203580 5μmol/L;SB20358010μmol/L;SB203580 20μmol/L）;d）PD＋SB组（PD98059 5μmol/L＋SB203580 5μmol/L;PD98059 10μmol/L＋SB203580 10μmol/L;PD98059 20μmol/L＋SB203580 20μmol/L）。细胞计数法、MTT法检测细胞活性,RT-PCR检测成骨细胞TRPV6 mRNA。所得数据用x-±s表示,采用t检验进行统计学分析。结果随着PD98059和/或SB203580浓度的增加,细胞增殖活性有下降的趋势,二者联合作用时细胞活性低于二者单独作用。细胞计数法检测显示,PD98059与SB203580联合作用时,三种组合中细胞数均显著低于空白对照组,P〈0.01;同时也明显低于二者单独作用组细胞数量。碱性磷酸酶染色显示,联合用药组较单独用药细胞数明显减少,细胞体积变小,突起狭长,ALP染色阳性颗粒减少,随药物作用浓度增加上述变化更加显著。茜素红染色显示,钙结节与对照组比较数量少、体积小;10、20μmol/L联合作用组,细胞数减少更加明显,无钙结节形成。SB203580与PD98059二者联合应用显著抑制TR-PV6 mRNA的表达,5 mmol/L联合作用组即可明显抑制,随着作用浓度增加TRPV6 mRNA的表达量逐渐减少。结论 p44/42途径阻断剂PD98059能抑制成骨细胞增殖,明显降低成骨细胞TRPV6 mRNA表达,减少钙结节形成。p38途径阻断剂SB203580能抑制成骨细胞增殖,明显降低成骨细胞TRPV6 mRNA表达,减少钙结节形成。PD98059与SB203580在抑制成骨细胞增殖、降低成骨细胞TRPV6 mRNA表达、减少钙结节形成的作用方面存在协同作用。     

Urinary proteins from patients with nephrotic syndrome alters the signalling proteins regulating epithelial–mesenchymal transition

Aim:   Proteinuria plays an important role in the progression of tubulointerstitial fibrosis, but the mechanism for the differential renal damage induced by proteinuria is unknown. This study examined the effects of urinary proteins from patients with idiopathic minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) on several epithelial–mesenchymal transition (EMT)-related marker proteins in cultured proximal tubular HK-2 cells.
Methods:   Urinary proteins from MCD and FSGS patients were extracted by ultrafiltration and incubated with HK-2 cells; the expression of the cytokeratin-18, α-smooth muscle actin (α-SMA) and vimentin were assessed. p38 and extracellular regulated kinase (ERK) activation were measured by western blotting, and SB203580 (a p38 inhibitor) and PD98059 (an ERK1/2 inhibitor) were used to inhibit their activation.
Results:   It was observed that urinary proteins from FSGS patients more significantly induced the expression of α-SMA and vimentin and reduced cytokeratin-18 expression than those from MCD patients in HK-2 cells. Both ERK1/2 and p38 were activated by urinary proteins from MCD or FSGS patients. Pretreatment of the cells with SB203580 or PD98059 abolished the effect of urinary proteins from FSGS patients on the expression of α-SMA, vimentin and cytokeratin-18, while only SB203580 elicited this effect when cells were treated with urinary proteins from MCD patients.
Conclusion:   The urinary proteins from MCD and FSGS patients induced significant changes of EMT-related proteins through activation of distinct mitogen-activated protein kinase-related signalling pathways. Quality of proteinuria may play an important role in determining the severity and progression of tubular injury associated with different kidney diseases.     

Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by p42/p44 mitogen-activated protein kinase and p38 mitogen-activated protein kinase.

We previously showed that basic fibroblast growth factor (bFGF) activates p38 mitogen-activated protein (MAP) kinase via Ca2+ mobilization, resulting in interleukin-6 (IL-6) synthesis in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the effect of bFGF on the release of vascular endothelial growth factor (VEGF) in these cells. bFGF stimulated VEGF release dose dependently in the range between 10 and 100 ng/ml. SB203580, an inhibitor of p38 MAP kinase, markedly enhanced the bFGF-induced VEGF release. bFGF induced the phosphorylation of both p42/p44 MAP kinase and p38 MAP kinase. PD98059, an inhibitor of upstream kinase of p42/p44 MAP kinase, reduced the VEGF release. SB203580 enhanced the phosphorylation of p42/p44 MAP kinase induced by bFGF. The enhancement by SB203580 of the bFGF-stimulated VEGF release was suppressed by PD98059. The depletion of extracellular Ca2+ by [ethylenebis(oxyethylenenitrilo)]tetracetic acid (EGTA) or 1,2-bis-(O-aminophinoxy)-ethane-N,N,N,N-tetracetic acid tetracetoxymethyl ester (BAPTA/AM), a chelator of intracellular Ca2+, suppressed the bFGF-induced VEGF release. A23187, a Ca ionophore, or thapsigargin, known to induce Ca2+ release from intracellular Ca2+ store, stimulated the release of VEGF by itself. A23187 induced the phosphorylation of p42/p44 MAP kinase and p38 MAP kinase. PD98059 suppressed the VEGF release induced by A23187. SB203580 had little effect on either A23187-induced VEGF release or the phosphorylation of p42/p44 MAP kinase by A23187. These results strongly suggest that bFGF stimulates VEGF release through p42/p44 MAP kinase in osteoblasts and that the VEGF release is negatively regulated by bFGF-activated p38 MAP kinase.